美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

亞盛醫藥

16.79

+0.08000.48%

盤後：16.790.00000.00%19:30 EDT

成交量：3,353

成交額：5.71萬

市值：15.67億

市盈率：-7.22

高：17.12

開：17.00

低：16.79

收：16.71

52周最高：43.45

52周最低：16.36

股本：9,333.04萬

流通股本：7,158.28萬

量比：0.33

換手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-2.3258

每股收益(LYR):-1.9957

淨資產收益率：-236.63%

總資產收益率：-28.04%

市淨率：18.93

市盈率(LYR):-8.41

資料載入中...

總覽公司新聞資訊公告

亞盛醫藥獲香港聯交所批准從股票代碼中移除"B"，6月1日起生效

亞盛醫藥-B(06855)：受託人就2022年受限制股份單位計劃購買合共10萬股

亞盛醫藥-B(06855)：中英文簡稱將不再加上標記「B」

亞盛醫藥-B(06855)：於2026年美國臨床腫瘤學會年上公布多項臨床進展

亞盛醫藥Bcl-2抑制劑利生妥®獲 2026 版 CSCO系列指南多項重磅推薦

亞盛醫藥-B(06855)多項研究入選2026 ASCO

亞盛醫藥-B(06855)授出受限制股份單位及購股權

亞盛醫藥-B(06855)四項臨床前進展亮相2026年美國癌症研究協會 (AACR)年會，展現多重聯合治療潛力

光鮮銷售下的深層危機：亞盛醫藥的盈利困局與三大致命風險

加速佈局兒童實體瘤治療領域！亞盛醫藥 MDM2-p53 抑制劑APG-115獲CDE納入"星光計劃"

兩大血液瘤王牌爆賣5億元難救主，亞盛醫藥又虧了12億元，能否熬到創新藥盈利拐點｜財報異動透視鏡

华夏时报网

亞盛醫藥2025年報：雙引擎驅動下自我造血與全球創新加速

21世纪经济报道

「十億美元分子」雙核共振，亞盛醫藥-B(06855)加速全球創新價值兑現

【券商聚焦】中信建投證券維持亞盛醫藥(06855)「買入」評級基於商業化產品放量及國際化管線潛力

亞盛醫藥-B(06855)雙引擎驅動高增長，耐立克銷售按年大增81%

亞盛醫藥利生妥®獲納入多地商業健康險報銷

亞盛醫藥-B(06855)將在2026年美國癌症研究協會年會上公布四項最新臨床前進展

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/AAPG/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亞盛醫藥","latestPrice":16.79,"timestamp":1787688000000,"preClose":16.71,"halted":0,"volume":3353,"hourTrading":{"tag":"盘后","latestPrice":16.79,"preClose":16.79,"latestTime":"19:30 EDT","volume":59,"amount":989.13,"timestamp":1787700602574,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.004787552363853877,"floatShares":71582800,"shares":93330405,"eps":-2.325826,"marketStatus":"已收盤","change":0.08,"latestTime":"08-25 16:00:00 EDT","open":17,"high":17.12,"low":16.79,"amount":57069.015605,"amplitude":0.019749,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.325826,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":5,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":16.71,"postHourTrading":{"tag":"盘后","latestPrice":16.79,"preClose":16.79,"latestTime":"19:30 EDT","volume":59,"amount":989.13,"timestamp":1787700602574,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.331717},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-28.04%","roe":"-236.63%","lyrEps":-1.995679,"volumeRatio":0.331717,"shares":93330405,"dividePrice":0,"high":17.12,"amplitude":0.019749,"preClose":16.71,"low":16.79,"week52Low":16.36,"pbRate":"18.93","psRate":"16.39","week52High":43.45,"institutionHeld":0,"latestPrice":16.79,"eps":-2.325826,"divideRate":0,"volume":3353,"delay":0,"ttmEps":-2.325826,"open":17,"prevYearClose":26.24,"prevWeekClose":17,"prevMonthClose":17.425,"prevQuarterClose":17.56,"fiveDayClose":18.1991,"twentyDayClose":18.285,"sixtyDayClose":20.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"date":"2026-08-19","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2026/06","expectedEps":-0.44,"defaultRemindTime":1787126400000,"name":null,"time":"盤前","dateTimestamp":1787112000000,"actualEps":null},{"date":"2026-03-25","symbol":"AAPG","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":null,"defaultRemindTime":1774468800000,"name":null,"time":"盤後","dateTimestamp":1774411200000,"actualEps":null},{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盤前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.7778,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7778,"analysts":9,"updateTime":1781150400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2026-08-24","current":-7.218941,"percent":0.997455,"low":-76.454813,"twenty":-35.938804,"median":-19.000621,"eighty":-11.551223,"high":-7.057849,"avg":-25.110263,"sd":16.847133,"marketCap":1562114860.06},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-12","current":-22.941741,"twenty":-59.475774,"median":-35.943012,"eighty":-31.122625,"marketCap":3735810338.07},{"date":"2025-09-19","current":-21.785524,"twenty":-59.316014,"median":-35.857966,"eighty":-29.943039,"marketCap":3550375801.58},{"date":"2025-09-26","current":-21.102028,"twenty":-59.062646,"median":-35.66937,"eighty":-29.751262,"marketCap":3428719452.06},{"date":"2025-10-03","current":-22.266298,"twenty":-59.025902,"median":-35.30284,"eighty":-28.699054,"marketCap":3625414266.5},{"date":"2025-10-10","current":-21.050291,"twenty":-58.738293,"median":-35.189473,"eighty":-26.732175,"marketCap":3423480133.18},{"date":"2025-10-17","current":-19.80269,"twenty":-58.191808,"median":-34.731922,"eighty":-24.468638,"marketCap":3221889328.22},{"date":"2025-10-24","current":-19.801335,"twenty":-57.904825,"median":-34.477812,"eighty":-23.569995,"marketCap":3222890223.42},{"date":"2025-10-31","current":-19.321494,"twenty":-57.532716,"median":-34.141844,"eighty":-22.943557,"marketCap":3150231208.59},{"date":"2025-11-07","current":-18.112503,"twenty":-56.69325,"median":-33.992043,"eighty":-22.558349,"marketCap":2949090425.48},{"date":"2025-11-14","current":-19.583345,"twenty":-55.920234,"median":-33.485756,"eighty":-22.342071,"marketCap":3199584585.23},{"date":"2025-11-21","current":-17.547753,"twenty":-55.765092,"median":-33.408485,"eighty":-22.122489,"marketCap":2860955000.96},{"date":"2025-11-28","current":-18.539078,"twenty":-55.318442,"median":-33.361942,"eighty":-21.796498,"marketCap":3034915066.08},{"date":"2025-12-05","current":-18.33416,"twenty":-53.27811,"median":-33.187028,"eighty":-21.590149,"marketCap":3005486168.49},{"date":"2025-12-12","current":-17.062052,"twenty":-48.796704,"median":-32.920123,"eighty":-21.073758,"marketCap":2802301628.68},{"date":"2025-12-19","current":-16.188794,"twenty":-48.517949,"median":-32.72391,"eighty":-20.125041,"marketCap":2665447409.6},{"date":"2025-12-26","current":-15.347054,"twenty":-48.514967,"median":-32.664532,"eighty":-19.801335,"marketCap":2537308174.25},{"date":"2026-01-02","current":-14.520508,"twenty":-48.239817,"median":-32.57809,"eighty":-19.656119,"marketCap":2406972911.39},{"date":"2026-01-09","current":-15.636938,"twenty":-46.480698,"median":-32.420873,"eighty":-19.300607,"marketCap":2595562368.02},{"date":"2026-01-16","current":-14.792082,"twenty":-45.997596,"median":-31.846105,"eighty":-19.073232,"marketCap":2461528990.12},{"date":"2026-01-23","current":-14.451393,"twenty":-45.706429,"median":-31.242401,"eighty":-18.892753,"marketCap":2402559084.95},{"date":"2026-01-30","current":-13.594278,"twenty":-43.897892,"median":-30.891003,"eighty":-18.486342,"marketCap":2268064814.82},{"date":"2026-02-06","current":-13.215954,"twenty":-42.7913,"median":-29.979764,"eighty":-18.329609,"marketCap":2208187061.91},{"date":"2026-02-13","current":-13.314281,"twenty":-42.590497,"median":-29.752899,"eighty":-18.136415,"marketCap":2236446544.83},{"date":"2026-02-20","current":-13.322258,"twenty":-42.10164,"median":-29.751262,"eighty":-17.934704,"marketCap":2235292402.77},{"date":"2026-02-27","current":-13.022247,"twenty":-41.475205,"median":-29.511221,"eighty":-17.157024,"marketCap":2206480506.48},{"date":"2026-03-06","current":-12.669019,"twenty":-41.161756,"median":-28.176938,"eighty":-16.734267,"marketCap":2131116747.44},{"date":"2026-03-13","current":-12.688953,"twenty":-40.378179,"median":-26.74375,"eighty":-16.137082,"marketCap":2141399622.46},{"date":"2026-03-20","current":-11.937263,"twenty":-39.521832,"median":-25.944924,"eighty":-15.566094,"marketCap":2005434649.33},{"date":"2026-03-27","current":-12.020857,"twenty":-39.289753,"median":-24.396919,"eighty":-15.439715,"marketCap":2161491459.44},{"date":"2026-04-02","current":-13.548587,"twenty":-39.152841,"median":-23.731199,"eighty":-15.186721,"marketCap":2444436047.79},{"date":"2026-04-10","current":-12.693217,"twenty":-38.895939,"median":-23.387346,"eighty":-14.745986,"marketCap":2308441702.51},{"date":"2026-04-17","current":-13.620079,"twenty":-38.882244,"median":-22.946281,"eighty":-14.465216,"marketCap":2481253103.51},{"date":"2026-04-24","current":-12.083101,"twenty":-38.84865,"median":-22.780777,"eighty":-14.008358,"marketCap":2199221373.05},{"date":"2026-05-01","current":-11.527627,"twenty":-38.758432,"median":-22.499202,"eighty":-13.791914,"marketCap":2098243441.9},{"date":"2026-05-08","current":-10.968155,"twenty":-38.515761,"median":-22.389807,"eighty":-13.684651,"marketCap":2004129088.99},{"date":"2026-05-15","current":-10.082774,"twenty":-38.444183,"median":-22.266298,"eighty":-13.539734,"marketCap":1846775928.57},{"date":"2026-05-22","current":-10.707594,"twenty":-38.225934,"median":-22.137659,"eighty":-13.395768,"marketCap":1956144727.44},{"date":"2026-05-29","current":-10.055476,"twenty":-38.129026,"median":-21.923528,"eighty":-13.314281,"marketCap":1843351578.24},{"date":"2026-06-05","current":-8.909894,"twenty":-37.937734,"median":-21.785524,"eighty":-13.216389,"marketCap":1635661877.38},{"date":"2026-06-12","current":-8.93641,"twenty":-37.865895,"median":-21.603031,"eighty":-13.157057,"marketCap":1639076784.73},{"date":"2026-06-18","current":-8.353042,"twenty":-37.752402,"median":-21.278471,"eighty":-13.101714,"marketCap":1535636323.4},{"date":"2026-06-26","current":-7.824164,"twenty":-37.62092,"median":-21.066691,"eighty":-13.023474,"marketCap":1430786980.62},{"date":"2026-07-02","current":-8.952074,"twenty":-37.472757,"median":-20.67449,"eighty":-12.989985,"marketCap":1637864621.41},{"date":"2026-07-10","current":-9.338033,"twenty":-37.371981,"median":-19.946515,"eighty":-12.776282,"marketCap":1707700089.2},{"date":"2026-07-17","current":-9.151372,"twenty":-36.963176,"median":-19.801335,"eighty":-12.672971,"marketCap":1678950333.06},{"date":"2026-07-24","current":-9.04646,"twenty":-36.577605,"median":-19.676085,"eighty":-12.361815,"marketCap":1659751775.25},{"date":"2026-07-31","current":-8.626077,"twenty":-36.450857,"median":-19.539859,"eighty":-12.179575,"marketCap":1585151449.4},{"date":"2026-08-07","current":-9.281807,"twenty":-36.322679,"median":-19.321494,"eighty":-11.987055,"marketCap":1708580872.07},{"date":"2026-08-14","current":-9.158138,"twenty":-36.125575,"median":-19.172925,"eighty":-11.879713,"marketCap":1687515849.52},{"date":"2026-08-21","current":-7.057849,"twenty":-35.947221,"median":-19.05933,"eighty":-11.591162,"marketCap":1541157743.83},{"date":"2026-08-24","current":-7.150633,"twenty":-35.938804,"median":-19.000621,"eighty":-11.551223,"marketCap":1562114860.06}],"updateTime":1787697630932},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638651100","title":"亞盛醫藥獲香港聯交所批准從股票代碼中移除\"B\"，6月1日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2638651100","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638651100?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 11:06","pubTimestamp":1779937560,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年5月28日 /美通社/ --致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布，因公司已符合香港联交所上市规则第8.05条的市值/收益要求，日前已获得香港联交所批准，将于2026年6月1日起正式将\"B\"标记从股票代码中移除。亚盛医药于2019年10月28日通过18A规则在香港联交所主板挂牌上市，后陆续纳入深港通和沪港通股票名单。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4969934_ZH69934_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4969934_ZH69934_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","06855","AAPG","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638081685","title":"亞盛醫藥-B(06855)：受託人就2022年受限制股份單位計劃購買合共10萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638081685","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638081685?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 21:58","pubTimestamp":1779890296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2026年5月27日，受托人就2022年受限制股份单位计划目的于场内购买合共10万股现有股份以在归属后满足受限制股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1161","AAPG","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638501850","title":"亞盛醫藥-B(06855)：中英文簡稱將不再加上標記「B」","url":"https://stock-news.laohu8.com/highlight/detail?id=2638501850","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638501850?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 18:31","pubTimestamp":1779877916,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，由于相关规则不适用，公司的中英文简称自2026年6月1日起将不再加上标记“B”。公司的股份将以新英文股份简称“ASCENTAGE”及中文股份简称“亚盛医药”在联交所买卖。公司的股份代号维持不变，仍为“6855”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK4139","BK1574","06855","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637363327","title":"亞盛醫藥-B(06855)：於2026年美國臨床腫瘤學會年上公布多項臨床進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2637363327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637363327?lang=zh_tw&edition=fundamental","pubTime":"2026-05-22 07:46","pubTimestamp":1779407170,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，本公司六项入选2026年美国临床肿瘤学会年会的临床研究的摘要已于ASCO官网公布。本届ASCO年会将于2026年5月29日至2026年6月2日在芝加哥伊利诺伊州McCormick会议中心以线上线下结合的形式举办。该方案安全性可控，在儿童相关实体瘤中初步展现抗肿瘤活性，值得进一步研究。主要终点均为24周的主要分子学反应率。研究计划纳入约440例患者，在18个国家126个中心开展，目前正在招募中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG","BK1574","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630353293","title":"亞盛醫藥Bcl-2抑制劑利生妥®獲 2026 版 CSCO系列指南多項重磅推薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2630353293","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630353293?lang=zh_tw&edition=fundamental","pubTime":"2026-04-27 09:49","pubTimestamp":1777254540,"startTime":"0","endTime":"0","summary":"利沙托克拉是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。作为中国首个获批上市的国产原创Bcl-2抑制剂，此次利沙托克拉在 2026 版CSCO系列指南中的全面落地，充分展现了该产品在多个血液肿瘤领域的卓越临床价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4943806_ZH43806_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4943806_ZH43806_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["SG9999015945.SGD","LU1571399168.USD","LU1674673691.USD","BK4020","SG9999002224.SGD","AAPG","LU0203347892.USD","LU2102340556.USD","LU1778281490.HKD","LU2286300806.USD","LU0203345920.USD","SG9999015986.USD","BK4588","IE00B3PB1722.GBP","LU1066051498.USD","LU1221951129.SGD","LU1162221912.USD","CSCL","CSCO","LU2237443622.USD","CSCS","06855","LU0823417653.USD","LU0889566641.SGD","IE00BVYPNV92.GBP","LU0234570918.USD","LU2237443465.HKD","BK4533","BK1161","SG9999001424.SGD","LU1244550577.SGD","LU2247934214.USD","BK4579","BK4585","LU1267930813.SGD","LU2237443895.HKD","LU0348723411.USD","LU1883839398.USD","LU0234572021.USD","LU0868494708.USD","IE00B42XCP33.USD","LU1059921491.USD","IE00BSNM7G36.USD","LU0942090050.USD","LU1066053197.SGD","BK4560","BK1574","IE000M9KFDE8.USD","LU1066051811.HKD","LU1032955483.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629069553","title":"亞盛醫藥-B(06855)多項研究入選2026 ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2629069553","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629069553?lang=zh_tw&edition=fundamental","pubTime":"2026-04-22 07:05","pubTimestamp":1776812706,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)公布，公司三个重点品种的六项临床研究入选2026年美国临床肿瘤学会(ASCO)年会，其中三项获快速口头报告，三项获壁报展示。这三个重点品种分别为中国首个获批上市的第三代BCR-ABL抑制剂奥雷巴替尼(商品名：耐立克®)、中国首个获批上市的国产塬创Bcl-2选择性抑制剂利沙托克拉(商品名：利生妥®)和MDM2-p53抑制剂Alrizomadlin(APG-115)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1161","06855","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628721474","title":"亞盛醫藥-B(06855)授出受限制股份單位及購股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2628721474","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628721474?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 22:42","pubTimestamp":1776696140,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，截至本公告日期，已向2022年受限制股份单位计划的3名选定人士授出69.63万份受限制股份单位，相当于 69.63万股股份，其中向本公司执行董事兼首席执行官杨大俊博士(杨博士)授出39.38万份受限制股份单位;向本公司首席医学官兼主要股东翟一帆博士(翟博士)授出28.39万份受限制股份单位;及向本公司1名高级管理人员授出1.86万份受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","06855","AAPG","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628791678","title":"亞盛醫藥-B(06855)四項臨床前進展亮相2026年美國癌症研究協會 (AACR)年會，展現多重聯合治療潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=2628791678","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628791678?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 07:14","pubTimestamp":1776640456,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 公布，公司将在2026年美国癌症研究协会年会上以壁报形式公布四项临床前研究成果。该会议于2026年4 月17日至2026年4月22日在美国加州圣地亚哥举行。本次壁报涉及公司三个品种，包括：原创1类新药BCR-ABL抑制剂奥雷巴替尼、FAK/ALK/ROS1三联酪氨酸激酶抑制剂APG-2449、以及PRC2/EED抑制剂APG-5918。此外，公司针对BRAF突变肿瘤开展的APG-2449 研究、以及针对小细胞肺癌开展的APG-5918研究，凸显了公司聚焦攻克耐药机制、探索联合用药策略的战略方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","06855","BK1574","AAPG","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628208448","title":"光鮮銷售下的深層危機：亞盛醫藥的盈利困局與三大致命風險","url":"https://stock-news.laohu8.com/highlight/detail?id=2628208448","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628208448?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 19:01","pubTimestamp":1776423660,"startTime":"0","endTime":"0","summary":"在国产创新药赛道上，亚盛医药曾是最耀眼的明星之一。然而，其近日披露的2025年年报，却揭示了一家明星企业“销量猛增、亏损加剧”的典型困境。　　表面上看，核心产品耐立克销售额突破4.35亿元，整体商业化收入同比增长90%，似乎交出了一份不错的成绩单。但细究之下，公司全年净亏损高达12.43亿元，同比扩大206.4%，创下历史新高。这背后，隐藏着三大不可忽视的结构性风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-04-17/doc-inhuveqy6429410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AAPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627497821","title":"加速佈局兒童實體瘤治療領域！亞盛醫藥 MDM2-p53 抑制劑APG-115獲CDE納入\"星光計劃\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2627497821","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627497821?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 12:14","pubTimestamp":1776140040,"startTime":"0","endTime":"0","summary":"此次APG-115获纳入\"星光计划\"，将有助于公司与CDE的进一步紧密沟通，获得儿童人群研究过程中技术问题的针对性指导。APG-115此次获纳入CDE'星光计划'，是国家药监机构对该品种临床价值与研发前景的高度认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4933478_ZH33478_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4933478_ZH33478_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["APG","BK4139","LU1923622291.USD","06855","BK1574","LU1223083913.SGD","LU1223082196.USD","LU1223082519.USD","CDE","LU2125909916.SGD","BK4017","LU2125909759.SGD","BK4129","BK1161","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626338621","title":"兩大血液瘤王牌爆賣5億元難救主，亞盛醫藥又虧了12億元，能否熬到創新藥盈利拐點｜財報異動透視鏡","url":"https://stock-news.laohu8.com/highlight/detail?id=2626338621","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626338621?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 21:44","pubTimestamp":1775742264,"startTime":"0","endTime":"0","summary":"身披国产肿瘤原创新药领军者、细胞凋亡领域深耕者光环的创新药新贵亚盛医（06855.HK），近日披露的2025年年度报告无疑给市场扔下一枚深水炸弹，这份年报呈现了公司“产品销售猛增、整体业绩亏损”的矛盾反差。年报显示，亚盛医药的核心血液瘤产品矩阵表现亮眼，耐立克?（奥雷巴替尼）与利生妥?（利沙托克拉）合计实现销售收入5.06亿元，商业化收入同比大幅增长90%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093699953985.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699953985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","159992","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623574361","title":"亞盛醫藥2025年報：雙引擎驅動下自我造血與全球創新加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2623574361","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623574361?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 08:50","pubTimestamp":1774831800,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛2025年，对于中国创新药企亚盛医药（NASDAQ：AAPG；HKEX：6855）而言，是一个从“研发驱动”向“商业化与研发双轮驱动”跨越的关键之年。公司最新公布的2025年全年业绩，不仅交出了一份亮眼的商业化成绩单，更清晰地勾勒出其“全球创新”战略迈入全新阶段的蓝图。财报显示，报告期内，公司总收入5.74亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603303688161756.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603303688161756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622811719","title":"「十億美元分子」雙核共振，亞盛醫藥-B(06855)加速全球創新價值兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2622811719","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622811719?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 11:49","pubTimestamp":1774583348,"startTime":"0","endTime":"0","summary":"3月26日，亚盛医药-B2025年年度业绩正式出炉。“十亿美元分子”双核共振，夯实创新与全球化根基作为一家已经进入商业化加速阶段的创新药企业，亚盛医药在2025年最核心的价值研判锚点在于：不同于此前依靠耐立克“单点突破”，公司现阶段的全球商业化已步入“十亿美元分子”双核共振关键期。作为亚盛医药的第二款商业化产品，利生妥报告期内获批上市，为公司“十亿美元分子”双核共振奠定了重要基础，也成为公司业绩加速增长的关键一极。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06855","AAPG","BK4139","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622811531","title":"【券商聚焦】中信建投證券維持亞盛醫藥(06855)「買入」評級 基於商業化產品放量及國際化管線潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=2622811531","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622811531?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 11:17","pubTimestamp":1774581463,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，亚盛医药 2025年业绩符合预期，核心投资论点基于其商业化产品放量及国际化管线潜力。报告认为，公司核心产品奥雷巴替尼营收实现大幅增长，利沙托克拉商业化前景优异，且两款产品的多个全球三期临床持续推动，构成未来增长动力。另一产品利沙托克拉在上市后五个月实现销售收入7058万元。基于商业化放量及管线潜力，维持对亚盛医药-B的“买入”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977474","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622588314","title":"亞盛醫藥-B(06855)雙引擎驅動高增長，耐立克銷售按年大增81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622588314","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622588314?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 07:28","pubTimestamp":1774481290,"startTime":"0","endTime":"0","summary":"3月26日，头部创新药企业亚盛医药发布2025年全年业绩。作为公司首款商业化产品，耐立克在2025年迎来医保落地后的首个完整销售年份，销售额实现显著增长，达到4.35亿元人民币，同比大幅增长81%。公司第二款产品、中国首个上市的国产原创Bcl-2抑制剂利生妥自2025年7月获批后快速放量，截至报告期末的5个月内实现销售额7058万元人民币。业绩增长由已上市的两大核心产品“双引擎”高效驱动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","06855","AAPG","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621234097","title":"亞盛醫藥利生妥®獲納入多地商業健康險報銷","url":"https://stock-news.laohu8.com/highlight/detail?id=2621234097","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621234097?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 08:49","pubTimestamp":1774226940,"startTime":"0","endTime":"0","summary":"亚盛医药已在原创新药研发与临床开发领域建立经验丰富的国际化人才团队，以及成熟的商业化生产与市场营销团队。无论出现新信息、未来事件或其他情况，亚盛医药均无义务更新或修订任何前瞻性陈述。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4916192_ZH16192_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4916192_ZH16192_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK1574","06855","AAPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620041734","title":"亞盛醫藥-B(06855)將在2026年美國癌症研究協會年會上公布四項最新臨床前進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2620041734","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620041734?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 08:17","pubTimestamp":1773793027,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，本公司共有四项临床前研究进展入选2026年美国癌症研究协会年会。此次会议将于2026年4月17日至 2026年4月22日在美国加州圣地亚哥举行。从群体科学与预防，到癌症生物学、转化医学与临床研究，再到幸存者关怀与权益倡导，AACR年会全方位展示了前沿的癌症科学与医学成果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK4139","BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":37,"code":"91000000","status":"200"}]}}